CJC-1295 DAC Half-Life

What Is Half-Life and Why It Matters

Half-life is the time required for a substance to reduce to 50% of its initial concentration in the bloodstream. For peptides and drugs, half-life determines dosing frequency: compounds with short half-lives require frequent dosing to maintain therapeutic levels, while long half-life compounds maintain levels with infrequent dosing. CJC-1295 DAC's 6-8 day half-life is exceptionally long for a peptide, enabling practical once or twice-weekly dosing that's manageable for real-world use. In contrast, unmodified CJC-1295 (without the DAC moiety) has a 30-minute half-life, requiring daily injections to maintain blood levels.

Understanding half-life is critical for protocol design. If a dose is 2 mg and half-life is 6 days, after 6 days the remaining concentration is 1 mg; after 12 days (two half-lives), 0.5 mg remains. Steady-state levels are reached after approximately 5 half-lives (30-40 days), at which point each new dose maintains the same peak and trough pattern. For CJC-1295 DAC with a 6-8 day half-life and weekly dosing, steady-state is achieved by week 3-4, after which GH/IGF-1 levels remain relatively constant throughout the cycle.

The Drug Affinity Complex (DAC) Mechanism

Standard CJC-1295 is a 30-amino acid peptide with a 30-minute half-life due to rapid degradation by peptidases (enzymes that break down peptides) in the bloodstream. Scientists added a "Drug Affinity Complex"—a proprietary chemical moiety that conjugates CJC-1295 to albumin, the most abundant plasma protein. Albumin acts as a "cargo protein," carrying CJC-1295 through the bloodstream while protecting it from enzymatic degradation. This albumin binding extends half-life from 30 minutes to 6-8 days, a 200-fold increase.

The mechanism is elegant: CJC-1295 alone is rapidly degraded by serum peptidases, but when bound to albumin, the peptide portion is shielded from enzymatic attack. Albumin-bound CJC-1295 slowly dissociates and reassociates with new albumin molecules, creating a "depot effect" where the peptide is slowly released over days. Eventually, the bound peptide is cleared via normal renal and hepatic excretion, but the albumin recycling creates sustained circulating levels. This is why CJC-1295 DAC, despite being the same active compound as unmodified CJC-1295, produces such different pharmacokinetics and clinical effects.

CJC-1295 DAC vs. CJC-1295 Without DAC: Pharmacokinetic Comparison

Unmodified CJC-1295 (no DAC) requires daily injections to maintain therapeutic GH stimulation. A typical protocol is 100 mcg daily via subcutaneous injection. Blood CJC-1295 levels spike 10-20 minutes post-injection, remain elevated for approximately 30-45 minutes, then decline rapidly as peptidases degrade the compound. This produces pulsatile GH stimulation—5-10 GH pulses per day, mimicking the natural pulsatile GH secretion pattern. The advantage is physiologic GH release pattern; the disadvantage is inconvenience of daily injections and inability to achieve sustained GH elevation.

CJC-1295 with DAC allows 1-2 mg dosing once or twice weekly. Blood DAC-CJC-1295 levels peak 24-48 hours post-injection, then decline slowly over 6-8 days, reaching approximately 50% of peak by day 6-8. With weekly dosing, each new dose adds to residual levels from the previous dose, creating a "staircase" pattern where levels gradually climb weeks 1-3, then plateau at steady-state by week 4. This produces sustained GH elevation over 24 hours, rather than pulsatile spikes. Steady-state GH is lower per spike than unmodified CJC-1295 (which produces higher acute peaks), but total 24-hour GH exposure is significantly higher due to continuous stimulation.

Practically, this means CJC-1295 DAC is more convenient (weekly vs. daily) and produces superior chronic anabolic effects through sustained GH/IGF-1 elevation, despite lower acute GH peaks. The trade-off of lower acute peaks for continuous elevation is biochemically favorable for anabolic goals.

Steady-State Levels and GH/IGF-1 Elevation

With weekly 2 mg CJC-1295 DAC dosing, steady-state serum levels are reached by approximately week 3-4 of dosing. By steady-state, GH baseline levels are elevated approximately 2-4 fold above normal (from ~0.5 ng/mL baseline to 2-4 ng/mL sustained), and GH pulses in response to GHRH/CJC-1295 DAC stimulation produce peaks of 5-10 ng/mL above baseline. More importantly, IGF-1 (the primary mediator of GH's anabolic effects) increases 15-30%, reaching the upper normal range or slightly elevated (depending on baseline).

The steady-state GH elevation is clinically significant. Research in GH-deficient adults shows that sustained GH elevation in the 2-4 ng/mL range produces measurable increases in protein synthesis, fat mobilization, and muscle growth. The continuous elevation means muscle cells are under continuous anabolic stimulus, supporting rapid protein synthesis and slow-wave sleep quality 24/7, rather than the episodic stimulus of daily CJC-1295. This continuous signal appears to be more effective for lean mass gain and recovery than pulsatile dosing.

Reaching Steady-State: Pharmacokinetic Timeline

The timeline to reach steady-state is approximately 5 half-lives, or 30-40 days for CJC-1295 DAC with its 6-8 day half-life. Practically: Week 1 dosing (2 mg) produces initial GH elevation; residual level at day 7 is ~1 mg. Week 2 dosing (adding 2 mg to ~1 mg residual = ~3 mg total) increases cumulative levels. By week 3, residual from week 1 is ~0.25 mg, week 2 residual is ~1 mg, and new week 3 dose is 2 mg = ~3.25 mg total. By week 4, the pattern stabilizes at ~3.5-4 mg total circulating CJC-1295 DAC at peak post-injection, with troughs at ~1.5-2 mg pre-injection.

Practically, users don't notice "steady-state" as a discrete event. Instead, they notice progressive improvement weeks 1-4: week 1 minimal changes, week 2 slight improvements in sleep/recovery, week 3-4 accelerating results as GH stabilization produces cumulative effects. Results (muscle gain, fat loss, strength improvement) lag steady-state by 1-2 weeks, so maximal results appear by week 5-6 of dosing and continue through the cycle as steady-state GH provides continuous stimulus.

Dosing Frequency Options: Once-Weekly vs. Twice-Weekly

CJC-1295 DAC can be dosed either once weekly (2 mg single injection) or twice weekly (1 mg twice-weekly). Once-weekly dosing creates larger peaks and lower troughs; twice-weekly creates flatter levels with smaller fluctuations. From a GH response perspective, twice-weekly may be slightly superior because it maintains more stable levels, potentially improving sleep quality and reducing side effect variability. However, real-world outcomes appear similar between protocols—both achieve steady-state anabolic effects.

Practically, once-weekly is more convenient (one injection per week vs. two), so most users employ weekly dosing. Those sensitive to side effects or seeking maximum steady-state stability may prefer twice-weekly. The 6-8 day half-life means either protocol works; the choice is primarily convenience versus theoretical pharmacokinetic optimality.

Terminal Half-Life vs. Biological Half-Life

It's important to distinguish terminal elimination half-life (the time for blood concentration to decline 50%) from biological half-life (the time for the biological effect to decline 50%). CJC-1295 DAC's terminal elimination half-life is 6-8 days, but its biological half-life (time for GH response to decline 50%) may be slightly longer due to IGF-1's own half-life of 12-16 hours. This means even after CJC-1295 DAC levels drop, IGF-1 remains elevated longer, extending the biological effect. Practically, this means training performance and recovery remain good even as DAC levels approach trough before the next injection.

Comparison to Other GH Secretagogues

Different GH secretagogues have vastly different pharmacokinetics. Ipamorelin (GH secretagogue with 2-hour half-life) requires 2-3 times daily dosing to maintain GH stimulus. Hexarelin (GH secretagogue with 60-minute half-life) requires daily dosing. Unmodified CJC-1295 requires daily dosing. CJC-1295 DAC's 6-8 day half-life is exceptional among peptides, enabling practical once-weekly dosing. This is why CJC-1295 DAC is the most popular GH secretagogue for real-world use—superior convenience without sacrificing efficacy.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions on Half-Life

How long does CJC-1295 DAC stay in my system?

Half-life is 6-8 days. After one injection, approximately 50% remains after 6-8 days; 75% clears after 12-16 days. Biological effects (GH/IGF-1 elevation) remain measurable for approximately 14-21 days post-injection.

Is once-weekly dosing really sufficient?

Yes. Once-weekly dosing reaches steady-state and maintains continuous GH elevation. Twice-weekly provides slightly more stable levels but outcomes are similar.

What if I miss a dose?

Missing one weekly dose delays steady-state achievement by one week or temporarily lowers steady-state levels by approximately 25%, creating minimal disruption. Missing multiple consecutive doses returns you to baseline GH levels over 2-3 weeks.

Does the 6-8 day half-life mean I'm always elevated?

Yes. With weekly dosing, residual levels remain elevated continuously. GH doesn't "turn off" between doses; instead, it remains partially elevated, creating sustained anabolic stimulus.

How does half-life affect side effects?

Long half-life means side effects (water retention, joint aches) persist and accumulate during the cycle, only resolving 2-3 weeks post-discontinuation when blood levels decline below biological significance threshold.

Can I extend my cycle by skipping a dose?

Not effectively. Skipping a dose lowers levels but doesn't extend the cycle's biological benefit. Just continue normal dosing schedule or discontinue when cycle end-date is reached.